The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Clinical trial NCT00163085 · COMPLETED

Trial details

NCT number: NCT00163085
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Parkinson's Disease

Start date: 2005-05-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.